---
layout: default
title: Palivizumab
parent: Model Prediction Only (L5)
nav_order: 347
evidence_level: L5
indication_count: 10
last_modified_at: 2026-10-15
description: "Palivizumab: predicted new indication Benign neoplasm of tongue (evidence level L5). Approved use: Respiratory syncytial virus infection"
monitor_inn: "PALIVIZUMAB"
predicted_indications: ["benign neoplasm of tongue", "epiglottis neoplasm", "cervical neuroblastoma", "benign neoplasm of hypopharynx", "benign neoplasm of floor of mouth", "tumor of testis and paratestis", "cystic neoplasm", "schwannoma of jugular foramen", "mesenchymoma", "thyroglossal duct cyst"]
---

# Palivizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

# Palivizumab: From Respiratory Syncytial Virus Infection to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody originally used against **respiratory syncytial virus (RSV) infection**.
The TxGNN model predicts it may be effective for **benign neoplasm of tongue**, but **no clinical trials and no publications** currently support this prediction, which rests on a knowledge-graph score alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Respiratory syncytial virus infection (the approved indication text on the New Zealand licence is not available) |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| New Zealand Market Status | Cancelled only (no currently valid authorisation) |
| Number of Authorizations | 1 (0 valid, 1 cancelled) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Palivizumab is known to be a humanized monoclonal antibody that targets the F protein of RSV, and its use in RSV infection is established.

The data compiled for this report did not identify a mechanistic link between this antibody and benign tongue neoplasms. The RSV F protein has no known role in this tumour type, and an antiviral neutralizing antibody would not be expected to act on it. The high score (99.94%) most likely reflects proximity within the knowledge graph (for example, upper-airway or head-and-neck nodes) rather than pharmacology.

The other top-ranked predictions show the same pattern. All ten, including epiglottis neoplasm, cervical neuroblastoma, benign neoplasm of hypopharynx, benign neoplasm of floor of mouth, tumour of testis and paratestis, cystic neoplasm, schwannoma of jugular foramen, mesenchymoma and thyroglossal duct cyst, scored between 99.93% and 99.94%. None has a plausible mechanism, trials or literature. This clustering suggests a systematic model artifact rather than a genuine signal.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## New Zealand Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2621835 (cancelled) | Synagis | Injection, 100 mg per ml, 1 ml vial | Not available |

## Safety Considerations

Please refer to the package insert for safety information.

No drug-drug interaction records were found, and no contraindicated diseases were identified in the knowledge graph. This reflects missing data rather than confirmed safety.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has only a model score behind it (Evidence Level L5). There are no trials or publications, no plausible mechanism, and no currently valid New Zealand authorisation. The product's only licence has been cancelled.

**To proceed, the following is needed:**
- A credible biological rationale linking RSV F protein neutralization to the proposed tumour type, or preclinical data supporting one
- Mechanism of action data for palivizumab
- The Medsafe package insert, to review warnings and contraindications
- Confirmation of whether any palivizumab product is currently supplied in New Zealand
- Comparison with other predicted indications to check whether the model output is systematically biased toward head-and-neck tumours
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

